Earlier today, the Medicines and Healthcare products Regulatory Authority (MHRA) announced a consultation on how its legislation and regulatory processes would need to be modified in the unlikely event that the UK leaves the EU without a deal in March 2019.

The consultation builds on the Government’s technical notice published in August on how medicines, medical devices and clinical trials would be regulated if there’s no Brexit deal.

It covers proposed changes to four different Statutory Instruments:

  • Medicines for Human Use (Clinical Trials) Regulations 2004
  • Medical Devices Regulations 2002
  • Human Medicines Regulations 2012
  • Medicines (Products for Human Use) (Fees) Regulations 2016

The deadline for responding is 1 November.

Back to e-newsletter